Advertisement
Advertisement
PTGX
Protagonist Therapeutics, Inc
148.18
USDSponsored
+3.02
+2.08%
Sep 11, 15:59 UTC -4
Closed
Pre-Market
143.42
-4.76
-3.21%
PTGX Earnings Reports
Positive Surprise Ratio
PTGX beat 25 of 41 last estimates.
61%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$244.23M
/$2.11
Implied change from Q2 26 (Revenue/ EPS)
+14.41%
/-7.86%
Implied change from Q3 25 (Revenue/ EPS)
+5083.09%
/-440.32%
Protagonist Therapeutics, Inc earnings per share and revenue
On Aug 05, 2026, PTGX reported earnings of 2.29 USD per share (EPS) for Q2 26, beating the estimate of 2.12 USD, resulting in a 7.83% surprise. Revenue reached 213.47 million, compared to an expected 207.84 million, with a 2.71% difference. The market reacted with a +1.11% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of 2.11 USD, with revenue projected to reach 244.23 million USD, implying an decrease of -7.86% EPS, and increase of 14.41% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Protagonist Therapeutics, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Protagonist Therapeutics, Inc reported EPS of $2.29, beating estimates by 7.83%, and revenue of $213.47M, 2.71% above expectations.
How did the market react to Protagonist Therapeutics, Inc's Q2 2026 earnings?
The stock price moved up 1.11%, changed from $135.81 before the earnings release to $137.32 the day after.
When is Protagonist Therapeutics, Inc expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Protagonist Therapeutics, Inc's next earnings report?
Based on 12
analysts, Protagonist Therapeutics, Inc is expected to report EPS of $2.11 and revenue of $244.23M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.